| SEGMENT INFORMATION |
We follow the accounting guidance
of ASC 280 “Segment Reporting” (“ASC 280”). Reportable operating segments are determined based on the management
approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments
within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed
on a consolidated basis, the chief operating decision-maker manages the enterprise in five reportable segments, each with different operating
and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics, (iv) Cancer
Diagnostics and (v) Patent Licensing activities. The following represents selected financial information for our segments for the three
and nine months ended July 31, 2021 and 2020 and as of July 31, 2021 and October 31, 2020:
SCHEDULE
OF SEGMENT INFORMATION
| |
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
| |
|
For the Three Months Ended
July 31, |
|
|
For the Nine Months Ended
July 31, |
|
| |
|
2021 |
|
|
2020 |
|
|
2021 |
|
|
2020 |
|
| Net Income/(Loss): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
(1,618,860 |
) |
|
$ |
(417,502 |
) |
|
$ |
(4,025,354 |
) |
|
$ |
(1,542,865 |
) |
| Cancer Vaccines |
|
|
(1,464,323 |
) |
|
|
(178,738 |
) |
|
|
(3,033,026 |
) |
|
|
(544,605 |
) |
| Anti-Viral Therapeutics |
|
|
(1,262,260 |
) |
|
|
(281,098 |
) |
|
|
(2,052,821 |
) |
|
|
(590,602 |
) |
| Cancer Diagnostics |
|
|
(38,198 |
) |
|
|
(1,693,304 |
) |
|
|
(60,569 |
) |
|
|
(5,162,977 |
) |
| Patent Licensing |
|
|
(3,969 |
) |
|
|
(6,145 |
) |
|
|
114,894 |
|
|
|
(10,303 |
) |
| Total |
|
$ |
(4,387,610 |
) |
|
$ |
(2,576,787 |
) |
|
$ |
(9,056,876 |
) |
|
$ |
(7,851,352 |
) |
| Net Income/(Loss) |
|
$ |
(4,387,610 |
) |
|
$ |
(2,576,787 |
) |
|
$ |
(9,056,876 |
) |
|
$ |
(7,851,352 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Total operating costs and expenses |
|
$ |
4,388,236 |
|
|
$ |
2,435,969 |
|
|
$ |
9,571,149 |
|
|
$ |
7,735,975 |
|
| Less non-cash share-based compensation |
|
|
(3,187,326 |
) |
|
|
(1,041,799 |
) |
|
|
(5,224,697 |
) |
|
|
(3,173,219 |
) |
Operating costs and expenses
excluding non-cash share-based
compensation |
|
$ |
1,200,910 |
|
|
$ |
1,394,170 |
|
|
$ |
4,346,452 |
|
|
$ |
4,562,756 |
|
Operating costs and expenses excluding
non-cash share-based compensation: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
411,313 |
|
|
$ |
189,589 |
|
|
$ |
1,903,707 |
|
|
$ |
759,752 |
|
| Cancer Vaccines |
|
|
348,535 |
|
|
|
72,968 |
|
|
|
1,185,060 |
|
|
|
238,297 |
|
| Anti-Viral Therapeutics |
|
|
418,285 |
|
|
|
155,224 |
|
|
|
826,716 |
|
|
|
376,242 |
|
| Cancer Diagnostics |
|
|
20,645 |
|
|
|
971,698 |
|
|
|
37,368 |
|
|
|
3,180,511 |
|
| Patent Licensing |
|
|
2,132 |
|
|
|
4,691 |
|
|
|
393,601 |
|
|
|
7,954 |
|
| Total |
|
$ |
1,200,910 |
|
|
$ |
1,394,170 |
|
|
|
4,346,452 |
|
|
$ |
4,562,756 |
|
| Operating costs and expenses excluding non-cash share-based compensation |
|
$ |
1,200,910 |
|
|
$ |
1,394,170 |
|
|
|
4,346,452 |
|
|
$ |
4,562,756 |
|
| |
|
July 31,
2021 |
|
|
October 31,
2020 |
|
| Total assets: |
|
|
|
|
|
|
|
|
| CAR-T Therapeutics |
|
$ |
12,709,167 |
|
|
$ |
2,988,124 |
|
| Cancer Vaccines |
|
|
10,706,026 |
|
|
|
946,923 |
|
| Anti-Viral Therapeutics |
|
|
12,849,445 |
|
|
|
2,464,361 |
|
| Cancer Diagnostics |
|
|
682,943 |
|
|
|
2,869,529 |
|
| Patent Licensing |
|
|
114,810 |
|
|
|
184,027 |
|
| Total |
|
$ |
37,062,391 |
|
|
$ |
9,452,964 |
|
| Total assets |
|
$ |
37,062,391 |
|
|
$ |
9,452,964 |
|
Operating costs and expenses
excluding non-cash share-based compensation expense is the measurement the chief operating decision-maker uses in managing the enterprise.
|